loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for CCDC 710249, HCl salt

    Client Email Product
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Menu

    CCDC 710249, HCl salt

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alkermes Presents Analyses From Long-Term Safety Study of LYBALV at SIRS
    Alkermes Presents Analyses From Long-Term Safety Study of LYBALV at SIRS

    08 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alkermes-presents-analyses-from-long-term-safety-study-of-lybalvi-olanzapine-and-samidorphan-at-2024-congress-of-the-schizophrenia-international-research-society-302109802.html

    PR NEWSWIRE
    08 Apr 2024
    Share Share
    Alkermes Announces Topline Results From Study of LYBALVI
    Alkermes Announces Topline Results From Study of LYBALVI

    03 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alkermes-announces-topline-results-from-long-term-open-label-safety-and-durability-of-treatment-effect-study-of-lybalvi-olanzapine-and-samidorphan-302024987.html

    PR NEWSWIRE
    03 Jan 2024
    Share Share
    Alkermes' Lybalvi a new litmus test for mental illness marketing
    Alkermes' Lybalvi a new litmus test for mental illness marketing

    24 Feb 2022

    // Ben Adams FIERCEPHARMA

    https://www.fiercepharma.com/marketing/alkermes-lybalvi-a-new-litmus-test-for-mental-illness-marketing

    Ben Adams FIERCEPHARMA
    24 Feb 2022
    Share Share
    Alkermes Shows Positive Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI
    Alkermes Shows Positive Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI

    08 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/alkermes-announces-positive-topline-results-from-enlighten-early-phase-3b-study-of-lybalvi-in-patients-early-in-illness-301477193.html

    PRNEWSWIRE
    08 Feb 2022
    Share Share
    Alkermes schizophrenia drug gets U.S. FDA approval
    Alkermes schizophrenia drug gets U.S. FDA approval

    02 Jun 2021

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/alkermes-schizophrenia-drug-gets-us-fda-nod-2021-06-01/

    REUTERS
    02 Jun 2021
    Share Share
    FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
    FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831

    29 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/fda-accepts-alkermes-resubmission-of-new-drug-application-for-alks-3831-301198736.html

    PRNEWSWIRE
    29 Dec 2020
    Share Share